Invited Commentary
April 8, 2013

Glucagonlike Peptide 1–Based Drugs and Pancreatitis: Clarity at Last, but What About Pancreatic Cancer?Comment on “Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus”

Author Affiliations

Author Affiliations: Larry L. Hillblom Islet Research Center (Drs Gier and Butler) and Jonsson Comprehensive Cancer Center (Dr Butler), University of California, Los Angeles, David Geffen School of Medicine.

JAMA Intern Med. 2013;173(7):539-541. doi:10.1001/jamainternmed.2013.3374

The worldwide prevalence of type 2 diabetes mellitus (T2DM) is approaching 100 million.1 Most affected individuals are treated for decades. Not surprisingly, the market for drug treatment of T2DM is worth more than $20 billion per year. The most lucrative drugs are those still protected by patent and deemed worthy of selection despite high expense because of clear advantages over cheaper drugs no longer covered by patent protection.

First Page Preview View Large
First page PDF preview
First page PDF preview